Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999
Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999
复制标题
DOI：
10.1016/j.ophtha.2007.04.016
复制
发表时间：
2008-01-01
期刊：
影响因子：
13.7
通讯作者：
Yu, Fei
中科院分区：
文献类型：
--
作者：
Coleman, Anne L.;Yu, Fei
目的：视网膜相关性黄斑变性（AMD）是美国老年人失明和严重视力损害的主要原因。本研究旨在评估1995年至1999年非新生血管性和新生血管性AMD患者与对照组相比与眼睛相关的医疗费用，并描述5年内与眼睛相关的医疗费用在人口统计学和临床亚组中是否存在差异。设计：回顾性，观察性，基于人群的分析。参与者：医疗保险受益人的5%随机样本。方法：数据来自5%的医疗保险受益人随机样本，诊断为非新生血管性和新生血管性AMD。根据睑缘炎、慢性结膜炎或睑结膜炎的诊断选择对照组，而未诊断为AMD。在5年的研究期间，对每组的眼睛相关索赔进行了汇总和比较。人口统计学和临床因素可能影响眼睛相关costs.Main结果措施：眼睛相关的医疗费用在5年的研究period.Results：中位数眼睛相关的医疗费用估计为1607美元的新生血管性AMD患者，832美元的nonneovascular AMD患者，和658美元的控制。单因素和多因素分析显示，两组间的成本差异显著（P
Objective: Age-related macular degeneration (AMD) is the leading cause of blindness and severe visual impairment among the elderly in the United States. This study aims to assess eye-related Medicare costs from 1995 to 1999 in patients with both nonneovascular and neovascular AMD as compared with controls, and to delineate whether variations exist across demographic and clinical subgroups in eye-related Medicare costs over 5 years.Design: Retrospective, observational, population-based analysis.Participants: Five percent random sample of Medicare beneficiaries.Methods: Data were obtained from the 5% random sample of Medicare beneficiaries with diagnoses of nonneovascular and neovascular AMD. A control group was selected based on diagnoses of blepharitis, chronic conjunctivitis, or blepharoconjuctivitis and no diagnosis of AMD. Eye-related claims were totaled and compared for each group over the 5-year study period. Demographic and clinical factors potentially influencing eye-related costs were also examined.Main Outcome Measures: Eye-related Medicare costs during the 5-year study period.Results: Median eye-related Medicare costs were estimated at $1607 for neovascular AMD patients, $832 for nonneovascular AMD patients, and $658 for controls. Cost differences across groups were significant based on univariate and multivariate analyses (P